The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions FDA to weigh easing limits on unproven peptides promoted by RFK Jr. FDA moves toward easing restrictions on certain peptides BioPharma Dive